An Exploratory, Open-label, Non-randomized Phase 1 Study to Evaluate the Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in Patients With Alzheimer's Disease Compared to Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 20 Dec 2016
At a glance
- Drugs MNI 672 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Molecular NeuroImaging
- 15 Dec 2016 Status changed from active, no longer recruiting to completed.
- 16 May 2016 New trial record